Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center

BMC Pediatrics

Table 1 Clinical features and treatment of 21 cases of primary vaginal endodermal sinus tumor

Case number	Age at diagnosis (month)	Initial serum AFP (ng/ml)	Tumor size (cm)	FIGO stage	Treatment regimen	Cycles before sCR	Cycles after sCR	Relapse location	Follow-up outcomes	Follow-up time (month)
1	20	15,100	2	I	PEB5 + PEV3 + VAC*1	3	6	-	NED	281
2	44	646	5	I	PEB5 + PEV1 + VAC*1	2	5	-	NED	278
3	11	13,890	5	I	PEB*5	3	2	-	NED	206
4	11	10,268	5	I	PEB*6	3	3	-	NED	122
5	13	768	2	I	PEB*4	2	2	-	NED	118
6	11	1110	6	I	PEB*5	2	3	-	NED	111
7	8	4638	4	I	PEB*4	2	2	-	NED	100
8	10	8754	4	I	PEB1 + PEV3 + VAC*1	2	4	-	NED	96
9	7	29,887	6	I	PEB*5	3	2	-	NED	94
10	9	365	1	I	PEB*4	2	2	-	NED	80
11	11	1289	4	I	PEB*4	2	2	-	NED	71
12	28	251	1	I	PEB*4	2	2	-	NED	72
13	9	19,766	6	I	PEB5 + PE1	4	2	-	NED	69
14	8	2626	2	I	PEB*4	3	1	-	Dead of infection and heart failure	4
15	11	3293	3	I	PEB*5	3	2	Vagina (7 months after initial treatment)	NED	56
16	10	32,015	4	I	PEB*5	3	2	Vagina (3 months after last chemotherapy)	NED	49
17	4	1526	3	I	PEB*4	2	2	-	NED	44
18	36	54,000	7	I	Transabdominal vaginal lesion resection, PEB*10	3	7	-	NED	122
19	15	1000	5	II	Transabdominal vaginal lesion resection + internal iliac venous embolectomy, NVEB1 + PEB2	1	2	-	NED	62
20	32	33,147	9	I	CEB6 + PEV2 + PEB*5	-	-	-	DOD	10
21	10	6977	4	I	Transabdominal vaginal lesion resection, VPEB2 + CEB1 + PEB*2	3	2	-	NED	51

Abbreviations:
sCR, serologic complete remission; PEB, cisplatin, etoposide and bleomycin; PEV, cisplatin, etoposide and vincristine; VAC, vincristine, dactinomycin and cyclophosphamide; PE, cisplatin and etoposide; NVEB, nedaplatin, vindesine, etoposide and bleomycin; CEB, carboplatin, etoposide and bleomycin; VPEB, vincristine, cisplatin, etoposide and bleomycin; DOD, die of disease; NED, no evidence of disease

ISSN: 1471-2431